Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
An n-protein inhibitor is a drug or molecule designed to block the function of a virus’s nucleocapsid (N) protein, which helps package the virus’s genetic material and assists replication inside cells. For investors, these inhibitors matter because they represent a targeted antiviral strategy that could reduce viral replication and disease, potentially creating a new treatment opportunity; think of it as jamming a machine’s central gear to stop it from running.
phase 2bmedical
Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.
phase ii trialmedical
A phase II trial is a mid-stage clinical study that tests whether an experimental treatment works and what dose is effective and reasonably safe in a group of patients. Think of it as a pilot run that checks effectiveness and side effects before a larger final test; its results strongly influence a therapy’s remaining development time, regulatory chances and likely costs, so investors watch these outcomes as key value and risk signals.
placebo-controlledmedical
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
double-blindmedical
A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.
antiviral resistancemedical
Antiviral resistance occurs when a virus changes so medicines designed to stop it become less effective or stop working, often because the virus mutates and alters the part of itself the drug targets. For investors, resistance can reduce sales of existing therapies, force expensive reformulation or new clinical trials, change regulatory and public-health responses, and shift market share—like a key no longer fitting a lock, requiring new keys to be made.
viral loadmedical
Viral load is the measured amount of virus in a person’s sample (for example blood or saliva), usually reported as the number of virus particles per milliliter. Investors care because it acts like a thermometer for an infection—higher or falling levels show disease severity and whether treatments or vaccines are working, which directly affects demand for diagnostics, drugs, regulatory decisions, and a company’s sales prospects.
rsvmedical
Respiratory syncytial virus (RSV) is a common virus that infects the lungs and breathing passages, often causing cold-like symptoms in adults but potentially severe illness in infants, older adults, and people with weakened immune systems. Investors watch RSV because outbreaks and new tests, vaccines or treatments can drive demand, affect healthcare costs and hospital admissions, and influence regulatory approvals and revenues for companies working in diagnostics and respiratory medicines.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
WATERTOWN, Mass.--(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025 in Munich, Germany.
The first oral presentation will include results from RSVHR, the Phase 2b study of zelicapavir in high-risk adults, which were announced in September 2025, showing about a week improvement in complete symptom resolution and a lower hospitalization rate, and featuring new findings demonstrating strong exposure multiples over the EC90. The second oral presentation will highlight new data confirming zelicapavir’s high clinical and functional barrier against antiviral resistance, generated from the Phase 2 study in pediatric patients, which was announced in September 2024.
Details of the presentations are as follows:
Presentation Title: Zelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSV
Abstract Number: 3963
Date: April 18, 2026
Time: 8:30 a.m. CEST / 2:30 a.m. EDT
Location: Hall A1-3
Session Type: 2-hour Oral Session
Session Title: Three viruses, one winter: what we miss, what we treat, what comes next
Presenter: Scott T. Rottinghaus, M.D.
ePoster Title: Zelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trial
Abstract Number: 5360
Date: April 18, 2026
Time: 8:30 a.m. CEST / 2:30 a.m. EDT
Location: Arena 2
ePoster Number: E0043
Session Type: ePoster Flash Session
Session Title: Old viruses, new weapons: emerging antiviral therapies from bench to bedside
Presenter: John P. DeVincenzo, M.D.
Further information about ESCMID Global 2026 can be found here. Presentations will be available on the Company’s website here following each presentation.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
